Immediate Impact
2 from Science/Nature 53 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy
2024 Standout
Works of Daniel A. Weiser being referenced
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
2014
Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.
2011
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Daniel A. Weiser | 245 | 253 | 141 | 182 | 35 | 511 | |
| Sarah Burkhead Whittle | 289 | 222 | 80 | 123 | 33 | 525 | |
| Aleš Vícha | 221 | 235 | 100 | 252 | 49 | 573 | |
| Carla Manzitti | 226 | 114 | 139 | 82 | 33 | 478 | |
| Pablo Berlanga | 136 | 181 | 156 | 95 | 49 | 467 | |
| Raffaele Cozza | 82 | 211 | 150 | 103 | 38 | 534 | |
| Zsombor Melegh | 96 | 248 | 100 | 98 | 29 | 420 | |
| Jodi A. Muscal | 123 | 246 | 77 | 64 | 27 | 460 | |
| Zhixia Yue | 125 | 153 | 39 | 119 | 31 | 424 | |
| Angela D. Trobaugh‐Lotrario | 68 | 204 | 76 | 74 | 22 | 506 | |
| M. M. Uttenreuther-Fischer | 230 | 201 | 57 | 66 | 24 | 536 |
All Works
Login with ORCID to disown or claim papers
Loading papers...